Our work revolves around a simple premise: Put patients at the center of everything we do. For patients living with rare and aggressive cancers, our therapies have an opportunity to make a difference in their lives. By targeting the underlying tumor growth in patients with Notch-pathway activation, we may be able to deliver targeted therapy treatment options to address the unmet needs of people living with rare and often aggressive cancers.
ACC is a rare malignancy of the secretory glands, most commonly of the salivary glands. While major salivary glands are located in the mouth, there are minor salivary glands scattered throughout the aerodigestive tract and are mostly concentrated in cheeks, lips, tongue, palate and floor of the mouth. In addition to salivary glands, ACC can also arise in other sites outside the head and neck.
When presenting in the major salivary glands, ACC can cause symptoms of varying severity, including numbness, difficulty swallowing or paralysis of the facial nerve.
Ayala is currently in Phase 2 (ACCURACY) Clinical Trial for AL101 in patients with ACC bearing activated Notch mutations.
If approved, we believe that AL101 has the potential to be the first FDA-approved therapy for patients with R/M ACC.
Triple negative breast cancer is characterized by negative tests for three of the common receptors found in breast cancer: estrogen, progesterone, and HER2 protein. As a result, this means TNBC does not respond to hormonal therapy medicines or medicines to target the HER2 protein receptors.
TNBC is one of the most aggressive types of breast cancer. It is typically associated with a younger diagnosis age, advanced stage at diagnosis, increased risk of visceral metastasis and decreased survival.
Ayala is currently in Phase 2 (TENACITY) Clinical Trial for AL101 in patients with R/M TNBC bearing Notch activating alterations.
T-ALL is an aggressive, rare form of T-cell specific leukemia. T-ALL has an annual incidence of approximately 1,200 patients in the United States, of which an estimated 400 patients, including pediatric patients, present for the treatment of relapsed/refractory (R/R) T-ALL. Of patients with T-ALL, approximately 65% have Notch-activating mutations. In addition, there is an incremental subset of patients with Notch-pathway activation who do not bare Notch activating mutations.
T-ALL is characterized by chemotherapy resistance, induction failure and tendency for early relapse.
Ayala is set to commence with Phase 2 clinical trial of AL101 for the treatment of R/R T-ALL.
Desmoid tumors, also called aggressive fibromatosis, are rare, disfiguring, and often debilitating types of soft tissue tumors that arise in the extremities, abdominal wall, mesenteric root, chest wall and head and neck. They do not metastasize, but often aggressively infiltrate neurovascular structures and vital organs resulting in pain, loss of function, organ dysfunction, and in rare cases, death.
Desmoid tumors are typically diagnosed in patients between 15 and 60 years of age, more often in young adults, with a two- to three-fold female predominance and no significant racial or ethnic predilection.
Desmoid tumors have an annual incidence of approximately 1,700 patients in the United States. There are currently no FDA-approved therapies for patients with desmoid tumors.
Ayala is set to commence Phase 2 clinical trial of AL102 for the treatment of desmoid tumors.
Multiple Myeloma is a cancer of plasma cells. These cells, found mainly in bone marrow, make antibodies (called immunoglobins) that help the body attack and kill germs.
We are collaborating with Novartis to develop AL102 for the treatment of multiple myeloma (MM), in combination with Novartis’ B-cell maturation antigen (BCMA) targeting therapies.
The Novartis BCMA program is in Phase 1 clinical trial.